Follow LF0 researchXLinkedInSubstackFacebook
tput: No value for $TERM and no -T specified
lf0Research Desk
Menu

Research

CRISPR Therapeutics (CRSP) Stock Analysis & Research

Latest rating
Strong Sell
Latest report
Oct 26, 2026
Reports
1
Sector
Healthcare
All covered stocksHow our ratings performed

CRISPR Therapeutics AG, founded in 2013, is a gene-editing biopharmaceutical company listed on Nasdaq under CRSP. It develops CRISPR/Cas9-based medicines across four franchises: hemoglobinopathies, in vivo liver editing, CAR T cell therapy, and regenerative medicine.

Backtesting dashboard with equity curve and drawdown analysis
Quantitative market report dashboard with factor and risk analysis
SEC filing comparison with highlighted document changes

Most Popular Research

EOSEHOLDJun 22, 2026Eos Energy Enterprises Stock Analysis: EOSE Cash Burn, Revenue Growth & Financing RiskEos Energy Enterprises (EOSE) is rated Hold as rapid Q1 revenue growth is offset by persistent cash burn…SOUNSELLJun 14, 2026SoundHound AI Stock Analysis: Buy or Sell? Margin, Cash Burn & ValuationSoundHound AI (SOUN) carries a sell rating because strong revenue growth has not yet translated into self-funding economics.…AMKRSELLOct 21, 2026Amkor Technology Stock Analysis: AMKR Free Cash Flow, Valuation & Customer ConcentrationAmkor Technology (AMKR) is rated Sell as valuation remains rich while free cash flow is still negative. Customer…NVTSSELLOct 3, 2026Navitas Semiconductor Stock Analysis: Buy or Sell? Valuation & Cash BurnNavitas Semiconductor (NVTS) is rated Sell as the market prices in a turnaround that the latest numbers do…QXOHOLDJun 18, 2026QXO Stock Analysis: Valuation, Margins, Free Cash Flow & LeverageQXO, Inc. (QXO) is rated Hold as its valuation already prices in a recovery that has yet to…AEHRSELLJun 18, 2026Aehr Test Systems Stock Analysis: Valuation, Margins, Cash Flow & Customer RiskAehr Test Systems (AEHR) earns a SELL rating as its valuation far outpaces current earnings power. Revenue is…